To compare Hexvix® blue-light cystoscopy and standard white light cystoscopy for the detection of carcinoma in situ (CIS) in patients suspected of having high-risk bladder cancer
• 286 patients entered this European, multi-center, prospective, controlled, within-patient comparison of standard white light and Hexvix® blue-light cystoscopy; 211 were evaluated in the efficacy analysis • Patients were assessed with standard white light and blue-light cystoscopy 1 hour after Hexvix® instillation • The number and location of all suspicious areas identified under white light were mapped on a bladder chart. The light was then changed to blue-light mode and all fluorescing areas were identified and documented on the same bladder chart • All suspicious areas identified under white light were immediately biopsied or resected by transurethral resection. Additional biopsies were then obtained from all suspicious fluorescing lesions not previously identified by white light • One biopsy was taken from normal appearing urothelium as a reference for the pathologist • Assessment was by an independent central pathologist blinded to the identity of the lesion 
